La Jolla Pharmaceutical announced the availability of Giapreza (angiotesin II) injection for intravenous (IV) infusion to increase blood pressure in adults with septic or other distributive shock.
Giapreza, a vasoconstrictor, was initially approved by the Food and Drug Administration (FDA) in December 2017. The approval was based on the ATHOS-3 trial, a double-blind clinical study (n=321) of patients with shock and critically low blood pressure who remained hypotensive despite fluid or vasopressor therapy.
The most common adverse reactions reported in greater than 10% of Giapreza-treated patients were thromboembolic events. With regard to drug interactions, concomitant use of angiotensin converting enzyme (ACE) inhibitors may increase the response to Giapreza, while concomitant angiotensin II blockers (ARBs) may decrease the response.
Giapreza is available as a 2.5mg/mL strength solution in 1mL single-dose vials.
For more information call (800) 651-3861 or visit Giapreza.com.